2011
DOI: 10.1016/j.jpain.2010.09.006
|View full text |Cite
|
Sign up to set email alerts
|

Intra-Periaqueductal Gray Matter Microinjection of Orexin-A Decreases Formalin-Induced Nociceptive Behaviors in Adult Male Rats

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
22
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 58 publications
(23 citation statements)
references
References 25 publications
0
22
0
Order By: Relevance
“…The finding that intra-vlPAG microinjection of SB334867 reduced tail-flick latency in mice confirms the vlPAG as an important site of action for orexin-induced supraspinal antinociception (Ho et al, 2011;Azhdari-Zarmehri et al, 2011). In ob/ob mice, both the OX-A-mediated reduced-pain sensitivity and enhanced OFF-decreased ON cell activity were markedly reduced by treatment with AM251 at a dose inactive in wt mice, thus strongly suggesting that the CB 1 -mediated disinhibition produced by retrograde 2-AG after OX1-R receptor activation has a major role in OX-A-induced antinociception in the vlPAG.…”
Section: Discussionmentioning
confidence: 65%
“…The finding that intra-vlPAG microinjection of SB334867 reduced tail-flick latency in mice confirms the vlPAG as an important site of action for orexin-induced supraspinal antinociception (Ho et al, 2011;Azhdari-Zarmehri et al, 2011). In ob/ob mice, both the OX-A-mediated reduced-pain sensitivity and enhanced OFF-decreased ON cell activity were markedly reduced by treatment with AM251 at a dose inactive in wt mice, thus strongly suggesting that the CB 1 -mediated disinhibition produced by retrograde 2-AG after OX1-R receptor activation has a major role in OX-A-induced antinociception in the vlPAG.…”
Section: Discussionmentioning
confidence: 65%
“…Recording of nociceptive behaviors started after formalin injection (0 min) and was continued for 90 min. Formalin-induced nociceptive behaviours were calculated and evaluated separately during the phase 1 (1–7 min), inter-phase (8–14 min), the phase 2A (15–60 min) and the phase 2B (61–90 min) (Abbott, et al, 1995; Azhdari-Zarmehri, et al, 2011). …”
Section: Methodsmentioning
confidence: 99%
“…Neuropeptide Quantification It has been shown that neurotensin is implicated in analgesia via its actions within central and peripheral pain modulatory circuits, 23 oxytocin plays an antinociceptive role in the central nervous system, 2 and orexin is involved in nociceptive sensory processes. 3,24 Neuropeptides were determined by a Luminex (Luminex Corporation, Austin, TX) assay (Milliplex; EMD Millipore Corporation, Billerica, MA). This kit allows the simultaneous quantification of neurotensin, orexin A, and oxytocin (Milliplex HNP-35K; EMD Millipore Corporation).…”
Section: Outcome Measuresmentioning
confidence: 99%
“…61,68 Recent animal studies show that the analgesia produced by joint mobilization involves serotonin and noradrenaline receptors in the spinal cord, thereby performing a supporting role for central mechanisms of pain modulation. 60 Several neuropeptides, such as neurotensin, 23 oxytocin, 29 or orexin A, 3 have been associated with hypoalgesia and pain modulation, and it is well known that cortisol plays an analgesic role related to stress responses. 4,44 Recent theories have also suggested that chronic pain could be partly maintained by maladaptive physiological responses of the organism facing a recurrent stressor, a situation related to high cortisol levels.…”
mentioning
confidence: 99%